Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world treatment patterns, patient characteristics, and outcomes of cbtki-based therapies amongst a contemporary cohort of patients with R/R MCL in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

KMKami J. MaddocksMTMarsha TraceyDHDan He

Discussion

Loading...

Member takes

Overview

Observational study reveals poor outcomes and high-risk characteristics in patients with relapsed/refractory MCL receiving cbtki therapies.

Key Points

  • This study aimed to analyze treatment patterns and outcomes of patients with relapsed/refractory mantle cell lymphoma receiving cbtki therapies.
  • Utilized Flatiron Health electronic health record-derived database
  • Included adults with MCL starting systemic therapy after January 1, 2018
  • Analyzed treatment patterns and time-to-event outcomes for cbtki-based therapies
  • 745 patients received their first cbtki-based therapy in 2L+
  • Median time from diagnosis to cbtki initiation was 12.6 months
  • Overall median time-to-treatment-discontinuation was 8.0 months
  • 24-month overall survival was 56.5%

Cite This Study

Maddocks et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d477https://doi.org/10.1182/blood-2025-2725
View Full Paper
Ask AI
Bookmark
Share